ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

SCLC is an aggressive cancer type with high metastatic potential and bad prognosis. CTCs are a valuable source of tumor cells in blood circulation and are among the major contributors to metastasis. In this study we evaluated the number of CTCs that express PD-L1 in treatment-naïve ES-SCLC patients...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Anastasia Xagara, Argyro Roumeliotou, Alexandros Kokkalis, Konstantinos Tsapakidis, Dimitris Papakonstantinou, Vassilis Papadopoulos, Ioannis Samaras, Evagelia Chantzara, Galatea Kallergi, Athanasios Kotsakis
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	MDPI AG 2024-01-01
Seri Bilgileri:	Biomedicines
Konular:	ES-SCLC CTCs PD-L1<sup>+</sup>CTCs CD8<sup>+</sup> T-cells PD-1<sup>+</sup> T-cells ICI therapy
Online Erişim:	https://www.mdpi.com/2227-9059/12/1/146
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

ES-SCLC Patients with PD-L1<sup>+</sup> CTCs and High Percentages of CD8<sup>+</sup>PD-1<sup>+</sup>T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Benzer Materyaller